Holen Sie sich die Stockscreener-App
1.02
4.67%
-0.05
Schlusskurs vom Vortag:
$1.07
Offen:
$1.09
24-Stunden-Volumen:
173.35K
Relative Volume:
0.38
Marktkapitalisierung:
$15.49M
Einnahmen:
$356.60K
Nettoeinkommen (Verlust:
$-24.32M
KGV:
-0.1104
EPS:
-9.24
Netto-Cashflow:
$-27.24M
1W Leistung:
+0.99%
1M Leistung:
+2.07%
6M Leistung:
-61.36%
1J Leistung:
-42.70%
1-Tages-Spanne:
$1.02
$1.098
1-Wochen-Bereich:
$1.00
$1.16
52-Wochen-Spanne:
$0.73
$11.18
Geovax Labs Inc Stock (GOVX) Company Profile
Firmenname
Geovax Labs Inc
Sektor
Branche
Telefon
678-384-7220
Adresse
1900 LAKE PARK DRIVE, SMYRNA
Vergleichen Sie GOVX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GOVX
Geovax Labs Inc
|
1.02 | 15.35M | 356.60K | -24.32M | -27.24M | -9.24 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Geovax Labs Inc Stock (GOVX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-15 | Bestätigt | Alliance Global Partners | Buy |
| 2025-04-15 | Bestätigt | D. Boral Capital | Buy |
| 2024-11-11 | Eingeleitet | Alliance Global Partners | Buy |
| 2024-07-16 | Eingeleitet | ROTH MKM | Buy |
| 2020-11-19 | Eingeleitet | Maxim Group | Buy |
Geovax Labs Inc Aktie (GOVX) Neueste Nachrichten
GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Average Recommendation of “Buy” from Analysts - Defense World
GeoVax Congratulates Bipartisan Senate Action to Onshore Critical Medical Manufacturing - The Globe and Mail
GeoVax Labs (NASDAQ:GOVX) Shares Up 6.9% – Should You Buy? - Defense World
GeoVax Commends FDA's Shift to Risk-Based COVID-19 Vaccination Guidance - Yahoo Finance
GeoVax Applauds EQUIP-A-Pharma Initiative, Reinforces Commitment to Domestic Vaccine Manufacturing and Biodefense Innovation - Yahoo Finance
GeoVax Reaffirms Urgent Need for Multi-Antigen COVID-19 Vaccines as CDC Shifts Recommendations - Yahoo Finance
GeoVax Labs (GOVX) Projected to Post Earnings on Tuesday - Defense World
GeoVax Highlights Dual Protective Potential of GEO-CM04S1 Following Presentation at the AAI Annual Meeting 2025 - Yahoo Finance
GeoVax Strengthens Patent Portfolio for Innovative Cancer Therapy Approach - citybuzz -
GeoVax Expands Gedeptin(R) Patent Portfolio - Yahoo Finance
GeoVax Applauds White House Executive Order Supporting U.S. Pharmaceutical Manufacturing; Highlights Progress in Domestic MVA Vaccine Production - Yahoo Finance
Geovax highlights progress on mpox vaccine and COVID-19 trial advancements - MSN
GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia - ADVFN
D. Boral Capital Cuts GeoVax Labs (NASDAQ:GOVX) Price Target to $9.00 - Defense World
GeoVax Labs, Inc. (NASDAQ:GOVX) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Form 8-KCurrent report - ADVFN
Geode Capital Management LLC Has $223,000 Holdings in GeoVax Labs, Inc. (NASDAQ:GOVX) - Defense World
Analysts Offer Insights on Healthcare Companies: GeoVax Labs (GOVX) and Baxter International (BAX) - The Globe and Mail
GeoVax Labs Earnings Call: Mixed Sentiment and Future Prospects - TipRanks
Geovax Labs (GOVX) Faces Price Target Reduction by Analyst | GOV - GuruFocus
Geovax Labs (GOVX) Faces Price Target Reduction by Analyst | GOVX Stock News - GuruFocus
Apple To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
GeoVax Labs Reports Q1 2025 Progress Amid Challenges - TipRanks
Earnings call transcript: GeoVax Q1 2025 reveals revenue from BARDA contract - Investing.com
GeoVax Labs Q1 2025 Earnings Call Transcript - MarketBeat
GeoVax Reports First Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance
GeoVax Presents Gedeptin(R) Clinical Data at the American Association for Cancer Research Annual Meeting - Yahoo Finance
Geovax Labs is a buy, Roth says - Cantech Letter
GOVX’s 2023 Market Dance: Down -59.51% – Time to Invest? - investchronicle.com
Geovax Labs Inc (GOVX) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com
GeoVax Responds to Detection of Clade I Mpox in North Carolina Wastewater - Yahoo Finance
GeoVax Highlights Strong Clinical Results Following Presentation of Multi-Antigen COVID-19 Vaccine at the 25th Annual World Vaccine Congress - Yahoo Finance
GeoVax to Host Q1 2025 Financial Results Conference Call, Spotlight COVID-19 Vaccine and Cancer Therapy Progress - citybuzz -
GeoVax to Report First Quarter 2025 Financial Results and Provide Corporate Update on May 1, 2025 - The Globe and Mail
GeoVax Bolsters Technical Development with Seasoned Biologics Executive - citybuzz -
GeoVax Appoints Dr. Senthil Ranganathan as Vice President, Technical Development and CMC Operations - The Globe and Mail
Analysts Issue Forecasts for GeoVax Labs FY2029 Earnings - Defense World
HC Wainwright Estimates GeoVax Labs FY2025 Earnings - Defense World
Alliance Global Partners Cuts GeoVax Labs (NASDAQ:GOVX) Price Target to $8.50 - Defense World
HC Wainwright Reiterates Buy Rating for GeoVax Labs (NASDAQ:GOVX) - Defense World
Q2 EPS Estimates for GeoVax Labs Lowered by Noble Financial - Defense World
GeoVax Highlights New Study Demonstrating the Strength of Multi-Antigen COVID-19 Vaccine Candidates - Yahoo Finance
GeoVax Labs price target lowered to $14 from $18 at D. Boral Capital - Yahoo Finance
GeoVax Provides Update on BARDA Project NextGen and Outlines 2025 Business Momentum - Yahoo Finance
Geovax Labs stock hits 52-week low at $0.78 amid market challenges By Investing.com - Investing.com South Africa
Top Midday Decliners - marketscreener.com
These Numbers Reveal How Powerful Geovax Labs Inc (NASDAQ: GOVX) Stock Is - stocksregister.com
GeoVax Labs (GOVX) Faces Setback with Price Target Reduced by Ro - GuruFocus
GeoVax Labs (GOVX) Faces Setback with Price Target Reduced by Roth Capital | GOVX Stock News - GuruFocus
GeoVax to Present at the Emerging Growth Conference on April 16, 2025 - Yahoo Finance
GeoVax (GOVX) Faces Setback with Termination of COVID-19 Vaccine Project | GOVX Stock News - GuruFocus
Finanzdaten der Geovax Labs Inc-Aktie (GOVX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):